切换至 "中华医学电子期刊资源库"
高级检索
中华普通外科学文献(电子版)

中华普通外科学文献(电子版) ›› 2021, Vol. 15 ›› Issue (05) : 375 -379. doi: 10.3877/cma.j.issn.1674-0793.2021.05.013

论著

CUL4B与miR34a在直肠癌组织中的表达及临床意义
周道秋1,†(), 邱堃2, 赖子飞3, 陈太耀4   
  1. 1. 572200　五指山，海南省第二人民医院病理科
    2. 572200　五指山，海南省第二人民医院普通外科
    3. 572200　五指山，海南省第二人民医院检验科
    4. 572200　五指山，海南省第二人民医院放射科
  • 收稿日期:2021-05-07 出版日期:2021-09-28
  • 通信作者: 周道秋
  • 基金资助:
    海南省卫生健康行业科研项目(20A200116)

Expression and clinical significance of CUL4B and miR34a in rectal cancer

Daoqiu Zhou1,†(), Kun Qiu2, Zifei Lai3, Taiyao Chen4   

  1. 1. Department of Pathology, the Second People’ s Hospital of Hainan Province, Wuzhishan 572200, China
    2. Department of General Surgery, the Second People’ s Hospital of Hainan Province, Wuzhishan 572200, China
    3. Department of LaboratoryMedicine, the Second People’ s Hospital of Hainan Province, Wuzhishan 572200, China
    4. Department of Radiology, the Second People’ s Hospital of Hainan Province, Wuzhishan 572200, China
  • Received:2021-05-07 Published:2021-09-28
  • Corresponding author: Daoqiu Zhou
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

周道秋, 邱堃, 赖子飞, 陈太耀. CUL4B与miR34a在直肠癌组织中的表达及临床意义[J/OL]. 中华普通外科学文献(电子版), 2021, 15(05): 375-379.

Daoqiu Zhou, Kun Qiu, Zifei Lai, Taiyao Chen. Expression and clinical significance of CUL4B and miR34a in rectal cancer[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2021, 15(05): 375-379.

目的

探讨CUL4B与miR34a在直肠癌组织中的表达及与临床病理参数和预后的关系。

方法

收集2013年1月至2015年12月海南省第二人民医院80例直肠癌患者根治术切除的直肠癌组织和癌旁正常组织。采用免疫组织化学SP法检测癌组织和癌旁正常组织中CUL4B蛋白表达情况；qPCR法检测组织中CUL4B和miR34a mRNA的表达水平，并分析直肠癌组织中CUL4B和miR34a表达水平的相关性及与患者临床病理参数的关系；采用Kaplan-Meier生存曲线分析直肠癌患者5年生存率。

结果

CUL4B蛋白在直肠癌组织的阳性表达率为66.25%，显著高于癌旁组织中的35.0%（P<0.05）。癌旁组织和直肠癌组织中CUL4B mRNA表达水平分别为（1.03±0.11）和（2.18±0.16），miR34a表达水平分别为（1.95±0.08）和（0.89±0.19），差异有统计学意义（P<0.05）。直肠癌组织中CUL4B相对表达水平与miR34a相对表达水平呈明显负相关。CUL4B表达与分化程度、肝转移、T分期明显相关（P<0.05）；miR34a表达与分化程度、血管浸润、肝转移、T分期有关（P<0.05）。CUL4B低表达组和高表达组5年生存率分别为76.5%和54.3%；miR34a高表达组和低表达组5年生存率分别为71.1%和46.0%，差异均有统计学意义（P<0.05）。

结论

在直肠癌组织中CUL4B表达上调，miR34a表达下调，两者表达水平呈负相关关系。CUL4B和miR34a表达水平对直肠癌患者预后有显著影响，有望成为直肠癌预后评价的特异性指标。

关键词: 直肠肿瘤, CUL4B, miR34a, 预后
Objective

To investigate the expression of CUL4B and miR34a in rectal cancer and its relationship with clinicopathological parameters and prognosis.

Methods

From January 2013 to December 2015, 80 cases of rectal cancer tissues and adjacent normal tissues were collected from the Second People’ s Hospital of Hainan Province. The positive expression of CUL4B protein was detected by immunohistochemical SP method. The expression levels of CUL4B and miR34a mRNA in the patients’ tissues were detected by qPCR method, the correlation between the expression levels of CUL4B and miR34a and the relationship with the patients’ clinicopathological parameters were analyzed. Kaplan-Meier method was used to analyze the 5-year survival rate of patients.

Results

The positive expression rate of CUL4B protein in rectal cancer tissue was 66.25%, which was significantly higher than 35.0% in adjacent tissues (P<0.05). The expression levels of CUL4B mRNA in adjacent tissues and rectal cancer tissues were (1.03±0.11) and (2.18±0.16) respectively, and the relative expression levels of miR34a were (1.95±0.08) and (0.89±0.19) respectively, with significant differences (P<0.05). The relative expression level of CUL4B in rectal cancer tissue was significantly negatively correlated with the relative expression level of miR34a. The expression of CUL4B was significantly correlated with the degree of differentiation, liver metastasis, and T stage (P<0.05), and the expression of miR34a was significantly correlated with the degree of differentiation, vascular infiltration, liver metastasis, and T stage (P<0.05). The 5-year survival rates of the CUL4Blow-expression group and the high-expression group were 76.5% and 54.3% respectively, and miR34a high-expression group and the low-expression group were 71.1% and 46.0% respectively, and the differences were statistically significant (P<0.05).

Conclusions

The expression level of CUL4B is up-regulated and the expression level of miR34a is down-regulated in rectal cancer tissues, and its expression level is negatively correlated. The expression levels of CUL4B and miR34a have a significant impact on the prognosis of patients with rectal cancer, and they are expected to become specific indicators for the evaluation of the prognosis of rectal cancer.

Key words: Rectal neoplasms, CUL4B, miR34a, Prognosis
图1 CUL4B蛋白在直肠癌组织（A）及癌旁正常组织（B）中的表达（SP ×400）
图2 直肠癌组织中CUL4B相对表达水平和miR34a相对表达水平相关性分析
表1 CUL4B、miR34a表达与直肠癌患者临床病理参数的关系(例)
临床参数 CUL4B χ2值 P值 miR34a χ2值 P值
高表达(53例) 低表达(27例) 高表达(36例) 低表达(44例)
性别     0.053 0.817     0.005 0.945
  男 25 12     21 26    
  女 28 15     15 18    
年龄(岁)     0.086 0.769     0.002 0.964
  ≤60 30 17     19 23    
  >60 23 10     17 21    
肿瘤直径(cm)     0.773 0.379     1.552 0.213
  ≤5 22 14     23 22    
  >5 31 13     13 22    
分化程度     18.275 <0.001     15.709 <0.001
  低 6 0     2 16    
  中 38 10     26 27    
  高 9 17     8 1    
血管浸润     1.398 0.237     10.209 0.001
  无 24 16     26 16    
  有 29 11     10 28    
肝转移     17.169 <0.001     26.502 <0.001
  无 12 19     29 10    
  有 41 8     7 34    
T分期     8.591 0.035     9.093 0.028
  T1 1 0     3 2    
  T2 11 10     13 14    
  T3 22 15     19 16    
  T4 19 2     1 12    
图3 CUL4B、miR34a表达与直肠癌患者预后关系?A为CUL4B高表达组和低表达组5年生存率比较；B为miR34a高表达组和低表达组5年生存率比较
[1]
Shirouzu K, Murakami N, Akagi Y. Intersphincteric resection for very low rectal cancer: A review of the updated literature[J]. Ann Gastroenterol Surg, 2017, 1(1): 24-32.
[2]
Li P, Zhang L, Yang M, et al. Cul4B is a novel prognostic marker in cholangiocarcinoma[J]. Oncol Lett, 2017, 14(2): 1265-1274.
[3]
蒋百春, 龚瑶琴. 泛素连接酶复合物骨架蛋白CUL4B功能研究进展[J]. 中国科学:生命科学, 2018, 48(11): 1136-1151.
[4]
He F, Cheng XM, Gu WL. Effects of cullin 4B on the proliferation and invasion of human gastric cancer cells[J]. Mol Med Rep, 2018, 17(4): 4973-4980.
[5]
郭志平, 李恒, 陈健, 等. CUL4B在结肠癌组织的表达及意义[J]. 宁夏医科大学学报, 2017, 39(7): 2.
[6]
Orso F, Quirico L, Dettori D, et al. Role of miRNAs in tumor and endothelial cell interactions during tumor progression[J]. Semin Cancer Biol, 2020, 60: 214-224.
[7]
朱泽民, 徐涛. miR-34在肿瘤中的研究进展[J]. 国际病理科学与临床杂志, 2019, 39(11): 2525-2531.
[8]
Tomasi ML, Cossu C, Spissu Y, et al. S-adenosylmethionine and methylthioadenosine inhibit cancer metastasis by targeting microRNA 34a/b-methionine adenosyltransferase 2A/2B axis[J]. Oncotarget, 2017, 8(45): 78851-78869.
[9]
徐建波, 周星宇, 谢琴琴,等.结直肠癌奥沙利铂耐药关键基因的生物信息学分析及意义[J/CD]. 中华普通外科学文献（电子版）, 2020, 14（3）: 349-354.
[10]
万仁辉. CUL4B表达与结直肠癌临床病理特点及预后的关系[J/CD]. 消化肿瘤杂志（电子版）, 2016, 8(2): 86-90.
[11]
Yuan J, Han B, Hu H, et al. CUL4B activates Wnt/β-catenin signalling in hepatocellular carcinoma by repressing Wnt antagonists[J]. J Pathol, 2015, 235(5): 1-12.
[12]
Song B, Zhan H, Bian Q, et al. Knockdown of CUL4B inhibits proliferation and promotes apoptosis of colorectal cancer cells through suppressing the Wnt/β-catenin signaling pathway[J]. Int J Clin Exp Pathol, 2015, 8(9): 10394-10402.
[13]
Mi J, Zou Y, Lin X, et al. Dysregulation of the miR-194-CUL4B negative feedback loop drives tumorigenesis in non-small-cell lung carcinoma[J]. Mol Oncol, 2017, 11(3): 305-319.
[14]
Jia L, Yan F, Cao W, et al. Dysregulation of CUL4A and CUL4B ubiquitin ligases in lung cancer[J]. J Biol Chem, 2017, 292(7): 2966-2978.
[15]
Yang Y, Meng WJ, Wang ZQ. MicroRNAs in colon and rectal cancer - novel biomarkers from diagnosis to therapy[J]. Endocr Metab Immune Disord Drug Targets, 2020, 20(8): 1211-1226.
[16]
Liu N, Yang H, Yang L. Exploring the influence of microRNA miR-34 on p53 dynamics: A numerical study[J]. Commun Theor Phys, 2021, 73(3): 035601.
[17]
Xiong S, Hu M, Li C, et al. Role of miR34 in gastric cancer: from bench to bedside (Review)[J]. Oncol Rep, 2019, 42(5): 1635-1646.
[18]
Kim JS, Kim EJ, Lee S, et al. MiR-34a and miR-34b/c have distinct effects on the suppression of lung adenocarcinomas[J]. Exp Mol Med, 2019, 51(1): 1-10.
[1] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[2] 赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[3] 吴晖, 佴永军, 施雪松, 魏晓为. 两种解剖入路下行直肠癌侧方淋巴结清扫的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 40-43.
[4] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[5] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[6] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[7] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[8] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[9] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[10] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[11] 陈杰, 武明胜, 李一金, 李虎, 向源楚, 荣新奇, 彭健. 低位直肠癌冷冻治疗临床初步分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 494-498.
[12] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[13] 王灿, 樊昊, 张卫, 于冠宇. LARS 评分的研制回顾与应用现状[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 519-523.
[14] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号